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A Fluorogenic Histone Deacetylase Assay Well
Suited for High-Throughput Activity Screening
shown to be a tumor suppressor gene whose mutation
leads to a high risk of breast and ovarian cancer [7].
The role of HDAC was particularly highlighted by the
Dennis Wegener, Frank Wirsching, Daniel Riester,
and Andreas Schwienhorst*
Department of Molecular Genetics and
Preparative Molecular Biology recent finding that mutant retinoid receptors recruit
HDAC in acute promyelocytic leukemia [8–10]. Interest-Institute for Microbiology and Genetics
Grisebachstrasse 8 ingly, HDAC inhibitors such as trichostatin A (TSA) and
trapoxin (TPX) were shown to induce cell differentiation,37077 Goettingen
Germany cell cycle arrest, and reversal of transformed cell mor-
phology [11–13]. Not surprisingly, therefore, a number of
HDAC inhibitors show a potency as promising antitumor
agents [14–19]. The recent discovery of antimalarial ef-Summary
fects of certain HDAC inhibitors [20] further supports
the idea that HDACs could be key targets for chemother-Histone deacetylases (HDACs) are important enzymes
apeutic intervention in a variety of human diseases.for the transcriptional regulation of gene expression in
The discovery of novel HDAC inhibitors as new drugseukaryotic cells. Recent findings suggest that HDACs
for transcription therapy and cancer chemoprevention,could be key targets for chemotherapeutic interven-
however, is currently obstructed by the lack of suitabletion in malignant diseases. A convenient and sensitive
assay systems. By far, the most widely distributed assayfluorogenic assay for HDAC activity would therefore
of HDAC activity depends on the incubation of the en-expedite studies of HDAC in transcriptional regulation
zyme with acetate-radiolabeled histones [21] or peptideand in vitro screening for drug discovery. In this study,
substrates [22–27] followed by extraction with organicnovel fluorogenic substrates of HDACs were synthe-
solvents such as ethyl acetate and then the quantifica-sized with an -acetylated lysyl moiety and an adjacent
tion of the released radiolabeled acetic acid by liquidMCA moiety at the C terminus of the peptide chain.
scintillation count. 3H-histones are obtained by a labori-Upon deacetylation of the acetylated lysyl moiety, mol-
ous procedure that relies on the sacrifice of animals.ecules became substrates for trypsin, which released
The degree of acetylation of prelabeled core histoneshighly fluorescent AMC molecules in a subsequent
changes within different preparations and it is thereforestep of the assay. The fluorescence increased in direct
difficult to standardize the substrate properties. In con-proportion to the amount of deacetylated substrate
strast, labeled oligopeptides are synthesized by solid-molecules, i.e., HDAC activity. The nonisotopic, homo-
phase technology, and postlabeling HPLC purificationgeneous assay is well suited for high-throughput
is required. Although the classical radioactive assay hasHDAC inhibitor screening.
been successfully used to measure HDAC activities from
various sources, the need to separate product from sub-
Introduction strate limits assay throughput. In addition, the use of
scintillation cocktails makes these assays costly in
The reversible acetylation of histones is crucial for the terms of time, labor, and radioactive waste. Hence,
transcriptional regulation of gene expression in eukary- assays of this type are not readily amenable to automa-
otic cells. Discovered nearly 40 years ago [1], it has only tion and high-throughput screening.
recently become clear that acetylation of the  amino The scintillation proximity assay [28] in part solved
group of specific lysine residues within the positively the problem in that it does not require separation of
charged N-terminal tail of core histones H2A, H2B, H3, product and substrate nor does it use scintillation cock-
and H4 results in localized chromatin relaxation and a tails. However, since radioactivity is still involved, prob-
change in both histone-DNA and histone-nonhistone lems with exposure of laboratory personnel, monitoring,
protein interaction. In general, acetylation activity is cor- and decontamination of screening equipment as well as
related with transcriptional activation, whereas deace- disposal of radioactive waste remained unsolved.
tylation activity is accompanied by transcriptional re- The first principally nonisotopic methods for the deter-
pression [2–4]. Two classes of enzymes, histone mination of HDAC activity relied on immunoblotting of
acetyltransferases (HAT) and histone deacetylases hyperacetylated histones [29]. However, this approach
(HDAC), have been shown to maintain the delicate dy- has the drawback that rather than measuring enzyme
namic equilibrium in the acetylation level of nucleosomal activity in the presence or absence of inhibitor, these
histones and may very well be active in the regulation immunoblotting procedures more resembled functional
of other cellular processes as well [5]. tools that are not suited for assay throughput. The first
A growing body of experimental evidence indicates true nonisotopic assay for HDAC activity [30] used MAL
that the activity of HAT, and in particular, HDAC, affects (N-(4-methyl-7-coumarinyl)-N--(tert.-butyloxy-carbonyl)-
cell cycle arrest, terminal differentiation of different cell N--acetyllysinamide) as a substrate. Unfortunately,
types, and the pathogenesis of malignant disease [6]. formation of the deacetylated product is monitored by
The histone acetyltransferase BRCA2, for example, was HPLC and fluorescence detection after extraction with
ethyl acetate. Therefore, this assay is not exceptionally
well suited for high-throughput screening. In addition,*Correspondence: aschwie1@gwdg.de
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the substrate does not really well resemble acetylated
lysine residues in the original context of histones. Sur-
prisingly, however, the artificial substrate had an even
lower KM value (0.86 M) as compared to the natural
one (20 M) [30, 31]. Recent improvements of the assay
include: (1) fluorescence-labeled octapeptide sub-
strates [32] that bear some closer resemblance to the
native substrate; and (2) the introduction of an internal
standard [33, 34] for the quantification of fluorescence
substrate by HPLC. Although the assay was applied
successfully on a number of occasions, including the
study of time- and site-dependent deacetylation [33], it
still remains not readily amenable to automation and
high-throughput screening due to the necessary separa-
tion steps.
In principle, an assay could also be designed that
quantifies acetate enzymatically released from sub-
strates using an Acetic Acid Standard Test (No. 148261,
Roche Diagnostics, Mannheim, Germany). Briefly, ace-
tate is converted in the presence of acetyl-CoA synthe-
tase with ATP and CoA to acetyl-CoA. The latter reacts
with oxaloacetate to form citrate in the presence of ci-
trate synthetase. The oxaloacetate required for this re-
action is formed from L-malate and NAD in the presence
of L-malate dehydrogenase upon reduction of NAD to
NADH. As a signal, the absorbtion of NADH is moni-
tored at 340 nm. The test was recently adapted as an
assay system for acetate releasing enzymes [35] and
has already been applied to the characterization of a
putative acetylpolyamin amidohydrolase with similari-
ties to HDACs (C. Hildmann and A.S., unpublished data).
A similar assay has been introduced for HATs [36]. How-
ever, as yet, no application to HDAC activity measure-
ments has been reported.
The only method, so far, that has indeed been reported
Figure 1. Principle of the Histone Deacetylase Assayas an assay for high-throughput screening of a com-
pound library is a cell-based system using a stably inte- The assay comprises two steps. Step I: deacetylation of -acetylated
lysyl moieties in peptidic substrates. Step II: cleavage of deacet-grated reporter construct [37]. This system, however,
ylated substrates by trypsin and subsequent release of fluorescentdoes not discriminate between HDAC inhibitors and any
7-amino-4-methylcoumarin. Fluorescence measurement is done atother regulators of a tumor-suppressive pathway.
ex  390 nm and em  460 nm.Here, we present the synthesis and the in vitro evalua-
tion of a series of novel HDAC substrates that allow
of histone H4. The synthesis of Ac-Arg-Gly-Lys(Ac)-MCAmonitoring of HDAC activity via a novel type of sensitive
(8) was carried out as shown in Figure 2. First, the dipep-fluorogenic assay. The peptidic substrates contain an
tide Arg-Gly was synthesized by standard solid-phase-acetylated lysine residue followed by a 4-methylcou-
chemistry using H-Gly-2-chlorotrityl resin (1) and Fmoc-marin-7-amide moiety at their carboxy terminus. The
Arg(Pbf)-OH (2) preactivated with 2-(1H-benzotriazole-assay is a two-step enzymatic reaction (Figure 1). In the
1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)first reaction catalyzed by HDACs, acetate is released
and N-methylmorpholine (NMM). The immobilized di-from -acetylated lysine moieties. In the second reac-
peptide (3) was Fmoc-deprotected with piperidine fol-tion, the deacetylated peptides are recognized as sub-
lowed by acetylation of the N terminus with acetic anhy-strates by trypsin, which only cleaves after deacetylation
dride. The product (4) was cleaved from the supportof, and then after, lysine residues. The assay is intrinsi-
using TFA and subsequently purified by reversed phasecally nonradioactive and highly sensitive and does not
HPLC. The purified product was reacted with H-Lys(Ac)-demand the consumption of expensive material such
MCA (6), previously generated by Boc-deprotection ofas histones. Proof-of-concept experiments with TSA, a
Boc-Lys(Ac)-MCA (5). The final product (8) was obtainedwell-known inhibitor of HDAC, indicate that the new
from (7) by arginine deprotection using TFA and subse-assay is well suited for high-throughput screening ef-
quent semipreparative LC-MS. Ac-Gly-Gly-Lys(Ac)-MCA,forts in the process of identifying novel HDAC inhibitors
Ac-Leu-Gly-Lys(Ac)-MCA, and Ac-Gly-Ala-Lys(Ac)-MCAin large collections of candidate molecules.
were prepared in a similar way. For comparison, ver-
sions of all substrates with deacetylated lysine residuesResults
were also synthesized using the same procedure, ex-
cept that instead of (6), H-Lys(Z)-MCA was used, andSubstrates were derived from the sequence context
around acetylated lysine residues in the N-terminal tails final deprotection of Z was carried out in HBr/HOAc.
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Figure 2. Synthesis of Fluorogenic Substrate
Ac-Arg-Gly-Lys(Ac)-MCA
Reaction conditions: (a) Fmoc-Arg(Pbf)-OH
preactivated with TBTU, NMM and DMF at RT
for 1 hr; (b) piperidine, DMF, acetic anhydride,
and DIPEA at RT for 30 min and, subse-
quently, DMF, DCM, ether, TFA, and DCM at
RT for 1 hr; (c) TFA and DCM at RT for 1 hr;
(d) DMF, TBU, and NMM at RT for 2 hr; (e)
TFA at RT for 2 hr.
The HDAC assay was designed as a two-step enzy- with KM values of594 M as compared to 7 M for the
known trypsin substrate Tos-Gly-Pro-Arg-MCA. Amongmatic reaction. In the first step, HDAC releases the ace-
tate moiety from -acetylated lysine residues of the sub- the deacetylated versions of the substrates, Boc-Lys-
MCA was digested the least efficiently and only at verystrate peptides. Reaction conditions optimal for HDAC
activity are used. In the second step, the deacetylated high trypsin concentrations (0.5 g/ml). At this con-
centration, all other substrates were quantitatively di-peptides containing now unprotected lysine residues
are recognized by trypsin and subsequently cleaved to gested within less than 1 min. At lower trypsin concen-
trations (0.05 g/ml), only Ac-Leu-Gly-Lys-MCA achievedrelease 7-amino-4-methylcoumarin (AMC). The fluores-
cence enhancement approached 30-fold relative to both a digestion to completion within 12 min. In the following
and throughout this study, we used a final trypsin con-the concomitant unhydrolyzed substrate and the sub-
strate with an acetylated lysine residue. centration of 5 mg/ml and an incubation time of 20 min
to ensure the tryptic digest of even the least suitableFirst, the trypsin reaction was analyzed in greater de-
tail (Figure 3). Digestion of peptides with -acetylated substrate (i.e., Boc-Lys-MCA) going to completion. In
the standard HDAC assay, TSA (final concentration oflysine residues did not result in any measurable cleav-
age within 24 hr. In contrast, the nonacetylated forms 1 M) was added together with trypsin to completely
prevent HDAC action within the period of tryptic digest.of substrate peptides were cleaved by trypsin, although
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Figure 4. Time-Dependent Activity of Rat Liver HDAC
As substrates, (1) Ac-Gly-Ala-Lys(Ac)-MCA, (2) Ac-Leu-Gly-Lys(Ac)-
MCA, (3) Boc-Lys(Ac)-MCA, (4) Ac-Gly-Gly-Lys(Ac)-MCA and (5) Ac-
Arg-Gly-Lys(Ac)-MCA were used.
recombinant human HDAC 8 (Table 1). A number of
deacetylation reactions were carried out at substrate
concentrations between 0.1 and 500 M. Endpoint AMCFigure 3. Time-Dependent Cleavage of Various Substrates by
fluorescence was monitored for deacetylation times be-Trypsin
tween 5 and 60 min. The initial velocity was calculatedAs substrates, (1) Boc-Lys-MCA, (2) Ac-Gly-Ala-Lys-MCA, (3) Tos-
Gly-Pro-Arg-MCA, (4) Ac-Arg-Gly-Lys-MCA, (5) Ac-Leu-Gly-Lys(Ac)- using the first 10 min of the deacetylation reactions. A
MCA, and (6) Boc-Lys(Ac)-MCA were used. Trypsin cleavage was Hanes plot was prepared from the kinetic data to calcu-
carried out at two different trypsin concentrations; (A) 0.5 g/ml late KM and Vmax values (Table 1). With rat liver HDAC,and (B) 0.005 g/ml. Cleavage was monitored by measuring the
Boc-Lys(Ac)-MCA revealed a KM of 3.5 M, whereas allflurorescence of 7-amino-4-methylcoumarin released during the re-
tripeptide substrates yielded KM values between 26 andaction. Note that substrates AcLGK-AMC, AcGAK-AMC, AcRGK-
43 M, which more strongly resembles the KM valueAMC, and Tos-GPR-AMC show exactly the same cleavage charac-
teristics at a trypsin concentration of 0.5 g/ml (A). for histones (20 M) [30], the natural substrate. With
recombinant human HDAC 8 and Ac-Arg-Gly-Lys(Ac)-
MCA or Boc-Lys(Ac)-MCA as substrates, KM values
In general, 100 l of HDAC reaction mixture (containing of 500 M were obtained. This finding is supported
the substrate) was combined with 100 l of trypsin/TSA by the fact that a H4-derived peptide is also not a good
solution. Experiments with low volume cavity 1536-well substrate for the enzyme [38]. Interestingly, HDAC 8
microplates proved that reliable signals were also ob- contains a stretch of mainly acidic amino acids which
tained with 5 l HDAC reaction mixture and 5 l trypsin/ is not present in HDAC 1–3 and which may be responsi-
TSA solution (data not shown). ble for a more demanding substrate specificity.
Next, the substrates with -acetylated lysine residues To test the feasibility of the assay for the identification
were used to monitor the enzymatic activity of rat liver of HDAC inhibitors, the assay was carried out in the
HDAC over time (Figure 4). In each case, aliquots of the presence of TSA, a known potent inhibitor of HDACs.
HDAC reaction were taken at different time points, and Inhibitor concentrations between 10	4 nM and 104 nM
the deacetylation reaction was stopped by the addition
of trypsin/TSA solution. After a 20 min incubation, the
AMC release was monitored by measuring the fluores-
Table 1. KM and Vmax Values for Selected HDAC Substratescence at ex  390 nm and em  460 nm using a BMG
Polarstar microplate reader (gain, 73). All substrates Rat Liver Histone Deacetylase*
were deacetylated similarly, as indicated by comparable
Peptide Sequence KM [M] Vmax [pmol s	1 mg	1]kinetics of AMC release. In addition, preliminary data
Boc-Lys(Ac)MCA 3.7 
 1.7 4.41 
 0.10on Boc-Lys(Ac)MCA indicate that at least this substance
Ac-Arg-Gly-Lys(Ac)MCA 27.5 
 4.9 3.61 
 0.29is also a suitable substrate to a recently discovered
Ac-Gly-Gly-Lys(Ac)MCA 32.6 
 3.2 4.27 
 0.26bacterial enzyme with similarities to acetylpolyamine
Ac-Leu-Gly-Lys(Ac)MCA 44.2 
 1.0 5.26 
 0.28
amidohydrolases (C. Hildmann and A.S., unpublished Ac-Gly-Ala-Lys(Ac)MCA 35.2 
 3.4 5.59 
 0.74
data).
* Rat liver HDAC (Calbiochem, Bad Soden, Germany), 89 U/ml, 4.7To characterize the substrates in more detail, KM and
mg/ml.
Vmax were determined for rat liver-derived HDAC and for
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strate and product differ chemically in one acetyl moiety,
but not significantly in their fluorescence properties, this
assay type absolutely requires separation steps prior
to fluorescence detection and is therefore intrinsically
nonhomogeneous.
Homogeneous fluorogenic assays are, however,
highly desirable, e.g., assays in which the quenched
(nonfluorescent) fluorophore is enzymatically released
as a then strongly fluorescent moiety in the scope of
the enzymatic reaction. A recent example of this type
of fluorogenic assay is the liberation of AMC by penicillin
G acylase [41].
The novel HDAC assay presented herein combines
the specificity of the deacetylation reaction with the
advantages of a homogeneous fluorogenic assay in a
two-step process. The HDAC substrates exhibit both an
-acetylated lysine residue within a histone-like se-
quence context and an adjacent essentially nonfluores-
cent 4-methyl-coumarine-7-amide residue. Following
deacetylation of the lysine residue, the product is recog-
nized by trypsin, which releases 7-amino-4-methylcou-
marin, a well-studied fluorophore detectable by stan-
dard fluorescence measurements. Since acetylated
HDAC substrates are not substrates for trypsin, AMC
fluorescence is correlated to deactetylase activity.
In our studies, four synthetic peptides, as well as the
commercially available Boc-Lys(Ac)-MCA, proved to be
well suited as substrates for the two-step assay. All
substrates presented here were recognized with signifi-
cant signal-to-noise ratio by rat liver HDAC. In addition,
Ac-Arg-Gly-Lys(Ac)-MCA was also shown to be a suit-
able substrate for recombinant human HDAC 8. Surpris-
ingly, all substrates, including Boc-Lys(Ac)-MCA, whichFigure 5. IC50 Measurements for Trichostatin A Using Rat Liver
HDAC (A) and Recombinant Human HDAC 8 (B) lacks extensive mimicry of the natural histone sub-
strates, show similar properties as far as KM and Vmax
values are concerned. Thus, it seems that the recogni-
TSA were used. All assays were performed with Ac-Arg- tion of -acetylated lysine residues by HDACs is rather
Gly-Lys(Ac)-MCA as a substrate at a final concentration insensitive to changes in sequence context. As a result,
of 250M. The semilogarithmic plots (Figure 5) analyzed it should be possible to generate peptidic HDAC sub-
with the help of the Graph Pad Prism software afforded strates of the type described here that are optimized
an IC50 value of 1.4 nM for rat liver HDAC, which is in with respect to the second assay reaction, i.e., trypsin
the range of the IC50 value of 2.6 nM reported recently cleavage. This could be desirable since current sub-
for the same enzyme and Boc-Lys(Ac)-MCA as the sub- strates are still not the most suitable substrates for tryp-
strate [33]. For recombinant human HDAC 8, the analysis sin and thus require not only rather large amounts of
of the semilogarithmic plot yielded an IC50 value of 53 trypsin, but also an inhibitory amount of trichostatin A
nM. The only IC50 value reported so far for this enzyme is to be added at the same time. This is particularly true
3 nM, as measured for the deacetylation of radioactively- for the commercially available Boc-Lys(Ac)-MCA, which
labeled histones [39]. The differences may be caused requires by far the highest trypsin concentrations as
by the usage of different substrates and assay types. well as long incubation times. Preliminary experiments
with Tos-Gly-Pro-Lys(Ac)-MCA, a derivative of a known
Discussion good substrate of trypsin [42], indicate that it also works
as a good substrate for rat liver HDAC, and in addition,
Fluorescence-based biological assays have been widely only requires trypsin concentrations 100-fold lower as
used to monitor reactions [40], in particular, in the con- compared to the standard conditions described herein.
text of high-throughput screening for inhibitors of phar- Concerning the substrate specificity in particular of
maceutically interesting target enzymes. Suitable assay HDACs, relatively little is known and hence predictions
formats, however, have not yet been developed for all about the general usability of the new assay type are
important targets. For HDACs, a particularly promising more speculative. Some studies suggest that only Sir2
class of new tumor targets, the most frequently used proteins, in contrast to class I and class II HDACs, have
assay type is still isotopic and nonhomogeneous in na- a specific globular domain that possibly is responsible
ture [21]. Only recently, the first type of fluorescence- for the recognition of the acetyl-lysine-containing sub-
based assay for HDACs was developed [30]. This assay, strate. The absence of a corresponding domain in class
I and class II enzymes suggests that other proteins mayhowever, only solved the problem halfway. Since sub-
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functionally substitute for this domain in vivo. Thus, as compared to Boc-Lys(Ac)-MCA. As a consequence,
the consumption of trypsin is much lower when usingclass I and class II HDACs may be relatively unspecific in
tripeptidic substrates. The feasibility of using thethe absence of such cofactors [43]. We would therefore
aforementioned probes for in vitro inhibition assays inconclude that our assay may very well be suited not
microplates was demonstrated by measurement ofonly for class I enzymes, as demonstrated for rat liver
IC50 values for TSA, a known HDAC inhibitor. IC50 valuesHDAC and human HDAC 8, but also for class II enzymes
of 1.4 nM determined with the rat liver enzyme and 53and even other classes of HDAC-like enzymes. This view
nM measured for recombinant human HDAC 8 wereis supported by the fact that the activity of a recently
in good agreement with previously published data. Thediscovered enzyme which belongs to the group of bac-
described method is thus a simple and sensitive homo-terial acetylpolyamine amidohydrolases can also be
geneous assay to characterize modulators of HDACmonitored using the new assay.
activity and is applicable to in vitro high-throughputThe main limitation of our assay is its inability to permit
screenings for HDAC inhibitors.continuous monitoring of enzyme activity, as is always
the case with endpoint assays. However, in the case of
Experimental Proceduresthe substrates reported here, continuous monitoring of
HDAC activity could, in principle, be achieved by replac- Synthesis of Fluorogenic Substrates
ing trypsin cleavage and subsequent standard fluores- For Ac-Arg-Gly-Lys(Ac)-MCA (8), H-Gly-2-chlorotrityl resin (1) (No-
vabiochem; 269 mg; 167 mol of reactive groups) was reacted forcence analysis by a measurement mode that images
1 hr at room temperature (RT) with 0.5 mmol of Fmoc-Arg(Pbf)-OHsensitively the chemical environment of the fluorophor.
(2) in N,N-dimethylformamide (DMF) (0.6 M) preactivated with 0.5It remains to be shown whether techniques such as
mmol TBTU (0.5 M in DMF) and 1.5 mmol NMM. The reaction mixturefluorescence intensity distribution analysis (FIDA) [44] was filtered, and the coupling step was repeated once. After filtra-
or burst-integrated fluorescence lifetime measurements tion, the resin-bound dipeptide (3) was Fmoc deprotected using 2
(BIFL) [45] could be suitable tools in this context. 2 ml 20% piperidine in DMF. Acetylation of the N terminus was
carried out by incubation with 2 ml 2.5% (v/v) acetic anhydride andThe assay described here is well suited in the context
2.5% (v/v) diisopropylethylamine (DIPEA) in DMF for 30 min at RT.of high-throughput screening for HDAC inhibitors, even
The reaction mixture was filtered, and the acetylation step wasin small reaction volumes. Potent inhibitors of trypsin,
repeated once. The resin was subsequently washed with 20 ml each
however, could impair assay results, e.g., in blocking of DMF, dichloromethane (DCM), and ether and finally dried in vacuo.
the AMC release from deacetylated substrates. There Cleavage of (1) was carried out in two subsequent reactions using
are at least two possible precautions that have to be 4 ml 3% trifluoroacetic acid (TFA) in DCM for 1 hr at RT. Evaporation
using an excess of hexane led to Ac-Arg(Pbf)-Gly-OH (4), having ataken. First, very high trypsin concentrations could be
yield of 80% with respect to the H-Gly-2-chlorotrityl resin. The crudeused to overcompensate inhibitor concentrations in or-
product was purified by reversed phase HPLC using a 250  10der to leave sufficient active trypsin for cleavage of
mm C18 column (Jupiter, Phenomenex, Aschaffenburg, Germany),
deacetylated substrate molecules. Second, a parallel eluted by methanol and dried in vacuo.
test of trypsin inhibition should be mandatory in order Boc-Lys(Ac)-MCA (5) (111.4 mg; Bachem, Switzerland) was
treated with 1 ml of 50% TFA in DCM for 1 hr at RT and dried byto exclude inhibition of the discriminator enzyme trypsin;
evaporation using an excess of hexane to form an azeotrope. Thethis is not necessarily a disadvantage since identified
product again was purified by reversed phase HPLC using a 250 deacetylase inhibitors are also optimized in specificity
10 mm C18 column (Jupiter, Phenomenex), eluted by methanol, and
as a result of such a procedure. dried in vacuo to yield pure H-Lys(Ac)-MCA (6). From both purified
products (4) and (6), 0.1 mmol was separately dissolved in 0.2 ml
DMF. Ac-Arg(Pbf)-Gly-OH (4) was preactivated with 0.1 mmol TBTU
Significance and 0.3 mmol of NMM and reacted with H-Lys(Ac)-MCA (6). After 2
hr at RT, the reaction was complete, as confirmed by LC-MS, and
the solvent was evaporated to give Ac-Arg(Pbf)-Gly-Lys(Ac)-MCAFluorogenic substrates of HDAC were prepared by
(7). The arginine protection group was cleaved within 2 hr in 90%chemical synthesis. These basically nonfluorescent
TFA. The solvent was evaporated, and the crude product was puri-
substrates featured: (1) a short peptide sequence de- fied using semipreparative LC-MS (Waters ZQ) with mass detection
rived from histone H4; (2) an acetylated lysyl moiety; as the trigger for fraction collection (Waters/MassLynx). The product
Ac-Arg-Gly-Lys(Ac)-MCA (8) was dried and produced a white pow-and (3) a subsequently following MCA moiety. Deace-
der in 60% yield. LC-MS (ESI): calculated for C28H40N8O7 (MH):tylation of acetylated lysyl moieties by HDAC yielded
601.31; found: 601.4.molecules that only then were efficient substrates for
Ac-Arg-Gly-Lys-MCA (9) was prepared in a similar way to (8).
trypsin. Cleavage by trypsin resulted in the release Instead of Boc-Lys(Ac)-MCA (5), H-Lys(Z)-MCA (10) (118 mg;
of AMC and, thereby, a fluorescence increase as a Bachem, Switzerland) was used to give a final yield of 30%. LC-MS
function of deacetylated molecules availability, i.e., the (ESI): calculated for C26H38N8O6 (MH): 559.30; found: 559.4.
Ac-Gly-Gly-Lys(Ac)-MCA (11), Ac-Leu-Gly-Lys(Ac)-MCA (12),extent of HDAC activity. The assay demonstrated an
Ac-Gly-Ala-Lys(Ac)-MCA (13), and their deacetylated counterparts30-fold enhancement of fluorescence monitoring re-
Ac-Gly-Gly-Lys-MCA (14), Ac-Leu-Gly-Lys-MCA (15), and Ac-Gly-actions with rat liver HDAC and recombinant human
Ala-Lys-MCA (16) were prepared as described for (8) and (9) using
HDAC 8. The substrate specificity of rat liver HDAC the appropriate building blocks. In each case, the overall yield was
was examined in greater detail. In regard to the deace- between 30 and 60%. LC-MS (ESI) for (11): calculated for C24H31N5O7
(MH): 502.23; found: 502.2. LC-MS (ESI) for (12): calculated fortylation reaction, Boc-Lys(Ac)-MCA is a slightly more
C28H39N5O7 (MH): 558.29; found: 558.2. LC-MS (ESI) for (13): calcu-favorable substrate as compared to the tripeptidic
lated for C25H33N5O7 (MH): 516.26; found: 516.2. LC-MS (ESI) forsubstrates Ac-Arg-Gly-Lys(Ac)-MCA, Ac-Gly-Gly-
(14): calculated for C22H29N5O6 (MH): 460.22; found: 460.3. LC-MSLys(Ac)-MCA, Ac-Leu-Gly-Lys(Ac)-MCA, and Ac-Gly- (ESI) for (15): calculated for C26H37N5O6 (MH): 516.28; found: 516.3.
Ala-Lys(Ac)-MCA. The latter, however, have the advan- LC-MS (ESI) for (16): calculated for C23H31N5O6 (MH): 474.24; found:
474.2.tage of being digested by trypsin significantly faster
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